Examining neuronal resilience in a mouse model of sporadic ALS

检查散发性 ALS 小鼠模型的神经元弹性

基本信息

  • 批准号:
    10381720
  • 负责人:
  • 金额:
    $ 35.22万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-04-01 至 2024-03-31
  • 项目状态:
    已结题

项目摘要

Project Summary/Abstract Following an injury to the brain, healthy neurons that are adjacent to the damaged area can sometimes take over the functions performed by the impaired neurons. This process has been best studied after acute nerve damage, but there is evidence that compensation by surviving neurons is also happening in the early stages of neurodegenerative diseases. In amyotrophic lateral sclerosis (ALS), the fiber type grouping in muscle samples taken from patients suggests that after an initial loss of connections between motor neurons (MNs) and muscles, new nerves are able to reconnect to allow patients to maintain movement during the disease process. A second observation made at the time of autopsy is that the vast majority of patients have an accumulation of a mislocalized protein called TDP-43 in the surviving MNs. However, because these cells are inaccessible in early disease stages, the molecular mechanisms for coping with disease processes in the MNs that send out new connections to muscles are unknown. In order to determine the dynamic responses that could allow a subpopulation of MNs to cope specifically with mislocalized TDP-43 and send out new axonal connections to muscles to prevent paralysis, we developed a mouse model in which we can induce neuronal expression of mislocalized human TDP-43, called rNLS8 mice. We then showed that rNLS8 mice have certain subsets of MNs that are uniquely vulnerable to disease, and that surviving MNs can effectively take the place of these cells, even late into the disease course. In this study, we will now identify the populations of MNs responsible for the reinnervation and restoration of function of vulnerable muscles after the initial TDP-43 triggered MN loss (Aim 1), using a combination of neuronal tracing techniques, muscle physiology, and imaging at the neuromuscular junction. We will then look for the upstream contribution of the brain's immune cells, microglia, to MN plasticity and the resultant circuit changes (Aim 2) by pharmacologically eliminating microglia and selectively reintroducing microglial derived factors that have been previously shown to influence neuronal function. Finally, molecular differences between MNs that innervate the same muscle before and after TDP-43 triggered axonal dieback will be uncovered by RNA- Sequencing and the top gene targets will be validated for their effect on motor function during ALS-like disease in rNLS8 mice (Aim 3). Completion of these studies should provide valuable insights into the potential mechanisms by which subsets of MNs can tolerate a build-up of cytoplasmic TDP-43. Moreover, understanding the mechanisms of neuronal compensation could allow for the development of therapies aimed at supporting surviving cells in order to extend their natural plasticity to slow disease and maintain function in patients.
项目总结/文摘

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

VIRGINIA M LEE其他文献

VIRGINIA M LEE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('VIRGINIA M LEE', 18)}}的其他基金

Pathogenesis of Tauopathies
Tau蛋白病的发病机制
  • 批准号:
    10583338
  • 财政年份:
    2023
  • 资助金额:
    $ 35.22万
  • 项目类别:
Project I "Mechanisms of Pathological aSyn Transmission"
项目一“病理性非同步传播机制”
  • 批准号:
    10373920
  • 财政年份:
    2019
  • 资助金额:
    $ 35.22万
  • 项目类别:
Center On Alpha-synuclein Strains In Alzheimer Disease & Related Dementias
阿尔茨海默病α-突触核蛋白菌株研究中心
  • 批准号:
    10654792
  • 财政年份:
    2019
  • 资助金额:
    $ 35.22万
  • 项目类别:
Project I "Mechanisms of Pathological aSyn Transmission"
项目一“病理性非同步传播机制”
  • 批准号:
    10452562
  • 财政年份:
    2019
  • 资助金额:
    $ 35.22万
  • 项目类别:
Project I "Mechanisms of Pathological aSyn Transmission"
项目一“病理性非同步传播机制”
  • 批准号:
    10020334
  • 财政年份:
    2019
  • 资助金额:
    $ 35.22万
  • 项目类别:
Center On Alpha-synuclein Strains In Alzheimer Disease & Related Dementias
阿尔茨海默病α-突触核蛋白菌株研究中心
  • 批准号:
    10452557
  • 财政年份:
    2019
  • 资助金额:
    $ 35.22万
  • 项目类别:
Examining neuronal resilience in a mouse model of sporadic ALS
检查散发性 ALS 小鼠模型的神经元弹性
  • 批准号:
    10610826
  • 财政年份:
    2019
  • 资助金额:
    $ 35.22万
  • 项目类别:
Center On Alpha-synuclein Strains In Alzheimer Disease & Related Dementias
阿尔茨海默病α-突触核蛋白菌株研究中心
  • 批准号:
    10373915
  • 财政年份:
    2019
  • 资助金额:
    $ 35.22万
  • 项目类别:
Project I "Mechanisms of Pathological aSyn Transmission"
项目一“病理性非同步传播机制”
  • 批准号:
    10654801
  • 财政年份:
    2019
  • 资助金额:
    $ 35.22万
  • 项目类别:
TDP-43 Proteinopathies in ALS-Dementia
ALS 痴呆中的 TDP-43 蛋白病
  • 批准号:
    8534672
  • 财政年份:
    2010
  • 资助金额:
    $ 35.22万
  • 项目类别:

相似海外基金

Amyotrophic Lateral Sclerosis: treating the circuit behind the disease
肌萎缩侧索硬化症:治疗疾病背后的回路
  • 批准号:
    MR/Y014901/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.22万
  • 项目类别:
    Research Grant
Dysregulation of RNA processing as a driver of motor neuron dysfunction in Amyotrophic Lateral Sclerosis
RNA 加工失调是肌萎缩侧索硬化症运动神经元功能障碍的驱动因素
  • 批准号:
    MR/Y014286/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.22万
  • 项目类别:
    Research Grant
Fasciculation IN Amyotrophic Lateral Sclerosis Using MUMRI (FINALSUM)
使用 MUMRI 治疗肌萎缩侧索硬化症的肌束颤动 (FINALSUM)
  • 批准号:
    MR/Y503502/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.22万
  • 项目类别:
    Research Grant
I-Corps: Developing A Blood-Based Biomarker for the Detection and Monitoring of Amyotrophic Lateral Sclerosis
I-Corps:开发一种基于血液的生物标志物,用于检测和监测肌萎缩侧索硬化症
  • 批准号:
    2317745
  • 财政年份:
    2023
  • 资助金额:
    $ 35.22万
  • 项目类别:
    Standard Grant
Development of CM-CS1 CAR Treg to Treat Amyotrophic Lateral Sclerosis (ALS)
开发 CM-CS1 CAR Treg 治疗肌萎缩侧索硬化症 (ALS)
  • 批准号:
    10696512
  • 财政年份:
    2023
  • 资助金额:
    $ 35.22万
  • 项目类别:
Targeted immunotherapy for amyotrophic lateral sclerosis and frontotemporal dementia
肌萎缩侧索硬化症和额颞叶痴呆的靶向免疫治疗
  • 批准号:
    10759808
  • 财政年份:
    2023
  • 资助金额:
    $ 35.22万
  • 项目类别:
Metrics for Brain Controlled Communication: A comprehensive review of clinical outcome assessments for communication brain computer interfaces in amyotrophic lateral sclerosis
脑控制通信指标:肌萎缩侧索硬化症通信脑机接口临床结果评估的全面综述
  • 批准号:
    10848139
  • 财政年份:
    2023
  • 资助金额:
    $ 35.22万
  • 项目类别:
Resolving the Role of Neuronal STING in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
解决神经元 STING 在肌萎缩侧索硬化症和额颞叶痴呆中的作用
  • 批准号:
    10606865
  • 财政年份:
    2023
  • 资助金额:
    $ 35.22万
  • 项目类别:
The Gut Microbiota as a Contributor to Sexual Dimorphism in Amyotrophic Lateral Sclerosis
肠道微生物群是肌萎缩侧索硬化症性别二态性的一个促成因素
  • 批准号:
    488892
  • 财政年份:
    2023
  • 资助金额:
    $ 35.22万
  • 项目类别:
    Operating Grants
The biochemical stratification of amyotrophic lateral sclerosis
肌萎缩侧索硬化症的生化分层
  • 批准号:
    MR/Y001095/1
  • 财政年份:
    2023
  • 资助金额:
    $ 35.22万
  • 项目类别:
    Fellowship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了